CF Patients Breathe Easier With Vertex Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
After announcing game-changing data from a Phase III trial of its cystic fibrosis drug, Vertex could be making waves in two major disease areas.
You may also be interested in...
Innovative Drug Development: Kalydeco Provides A Paradigm, FDA’s Spielberg Says
The deputy commissioner detailed the steps involved in getting Vertex’s cystic fibrosis drug rapidly through the approval process and noted that FDA is working on innovative study designs and assessing how to better use diagnostics.
Vertex's Cystic Fibrosis Drug Kalydeco Could See Speedy Review
High unmet medical need, a genetically targeted patient population and the drug's biological rationale could combine for a faster-than-six-month approval for the novel, disease-modifying therapy.
Vertex's Cystic Fibrosis Drug Kalydeco Could See Speedy Review
High unmet medical need, a genetically targeted patient population and the drug's biological rationale could combine for a faster-than-six-month approval for the novel, disease-modifying therapy.